Below are the most recent publications written about "Poly(ADP-ribose) Polymerase Inhibitors" by people in Profiles.
-
Quinn Z, Leiby B, Sonpavde G, Choudhury AD, Sweeney C, Einstein D, Szmulewitz R, Sartor O, Knudsen K, Yang ES, Kelly WK. Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer. Clin Cancer Res. 2023 01 04; 29(1):50-59.
-
Mahtani R, Niyazov A, Arondekar B, Lewis K, Rider A, Massey L, Lux MP. Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from the United States, Europe, and Israel. BMC Cancer. 2022 Dec 22; 22(1):1343.
-
Arnold MR, Langelier MF, Gartrell J, Kirby IT, Sanderson DJ, Bejan DS, ?ileikyte J, Sundalam SK, Nagarajan S, Marimuthu P, Duell AK, Shelat AA, Pascal JM, Cohen MS. Allosteric regulation of DNA binding and target residence time drive the cytotoxicity of phthalazinone-based PARP-1 inhibitors. Cell Chem Biol. 2022 12 15; 29(12):1694-1708.e10.
-
Herzog TJ, Vergote I, Gomella LG, Milenkova T, French T, Tonikian R, Poehlein C, Hussain M. Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective. Eur J Cancer. 2023 Jan; 179:136-146.
-
Ogden TEH, Yang JC, Schimpl M, Easton LE, Underwood E, Rawlins PB, McCauley MM, Langelier MF, Pascal JM, Embrey KJ, Neuhaus D. Dynamics of the HD regulatory subdomain of PARP-1; substrate access and allostery in PARP activation and inhibition. Nucleic Acids Res. 2021 02 26; 49(4):2266-2288.
-
Shao Z, Lee BJ, Rouleau-Turcotte É, Langelier MF, Lin X, Estes VM, Pascal JM, Zha S. Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo. Nucleic Acids Res. 2020 09 25; 48(17):9694-9709.
-
Ramakrishnan Geethakumari P, Schiewer MJ, Knudsen KE, Kelly WK. PARP Inhibitors in Prostate Cancer. Curr Treat Options Oncol. 2017 Jun; 18(6):37.
-
Hu ZI, Ho AY, McArthur HL. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer. Int J Radiat Oncol Biol Phys. 2017 09 01; 99(1):153-164.
-
Pishvaian MJ, Biankin AV, Bailey P, Chang DK, Laheru D, Wolfgang CL, Brody JR. BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer. Br J Cancer. 2017 Apr 11; 116(8):1021-1026.
-
Illuzzi G, Fouquerel E, Amé JC, Noll A, Rehmet K, Nasheuer HP, Dantzer F, Schreiber V. PARG is dispensable for recovery from transient replicative stress but required to prevent detrimental accumulation of poly(ADP-ribose) upon prolonged replicative stress. Nucleic Acids Res. 2014 Jul; 42(12):7776-92.